Central mineralocorticoid receptor blockade decreases plasma TNF-α after coronary artery ligation in rats

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 284, Issue 2 53-2, 2003, Pages

  Francis, Joseph ^a   Weiss, Robert M ^a,d   Johnson, Alan Kim ^b,c   Felder, Robert B ^a,c,d  

^a UNIVERSITY OF IOWA   (United States)

^b E11 SSH   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Myocardial infarction; Spironolactone; Tumor necrosis factor

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALDOSTERONE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HORMONAL REGULATION; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0037305678     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00376.2002     Document Type: Article

References (73)

1. Anderson NSD and Fanestil DD. Corticoid receptors in rat brain: evidence for an aldosterone receptor. Endocrinology 98: 676-684, 1976.
2. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson PA, and Coats AJ. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96: 526-534, 1997.
3. Antonipillal I, Wang Y, and Horton R. Tumor necrosis factor and interleukin-1 may regulate renin secretion. Endocrinology 126: 273-278, 1990.
4. Bataillard A, del Rey A, Klusman I, Arditi GM, and Besedovsky HO. Interleukin-1 stimulates aldosterone secretion: involvement of renin, ACTH, and prostaglandins. Am J Physiol Regul Integr Comp Physiol 263: R840-R844, 1992.
5. Bataillard A and Sassard J. Cardiovascular effects of human recombinant interleukin-1 beta in conscious rats. Am J Physiol Regul Integr Comp Physiol 266: R1148-R1153, 1994.
6. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, and Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97: 1382-1391, 1998.
7. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz 25: 299-306, 2000.
8. Brody MJ and Johnson AK. Role of the anteroventral third ventricle region in fluid and electrolyte balance, arterial pressure regulation, and hypertension. In: Frontiers in Neuroendocrinology, edited by Martini L and Ganong WF. New York: Raven, 1980, p. 249-292.
9. Brody MJ. Central nervous system and mechanisms of hypertension. Clin Physiol Biochem 6: 230-239, 1988.
10. Bunnemann B, Fuxe K, and Ganten D. The brain renin-angiotensin system: localization and general significance. J Cardiovasc Pharmacol 19, Suppl 6: S51-S62, 1992.
11. Catt KJ, Millan MA, Wynn PC, Mendelsohn FA, and Aguilera G. Brain receptors for hypothalamic hormones. Adv Biochem Psychopharmacol 43: 51-67, 1987.
12. Chikanza IC, Petrou P, and Chrousos G. Perturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implications. Ann NY Acad Sci 917: 825-834, 2000.
13. Chrousos GP. The stress response and immune function: clinical implications. The 1999 Novera H Spector Lecture. Ann NY Acad Sci 917: 38-67, 2000.
14. Das UN. Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction. Mol Cell Biochem 215: 145-152, 2000.
15. De Kloet ER, Van Acker SA, Sibug RM, Oitzl MS, Meijer OC, Rahmouni K, and de Jong W. Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int 57: 1329-1336, 2000.
16. De Nicola AF, Grillo C, and Gonzalez S. Physiological, biochemical and molecular mechanisms of salt appetite control by mineralocorticoid action in brain. Braz J Med Biol Res 25: 1153-1162, 1992.
17. De Nicola AF, Seltzer A, Tsutsumi K, and Saavedra JM. Effects of deoxycorticosterone acetate (DOCA) and aldosterone on Sar1-angiotensin II binding and angiotensin-converting enzyme binding sites in brain. Cell Mol Neurobiol 13: 529-539, 1993.
18. Delcayre C, Silvestre JS, Garnier A, Oubenaissa A, Cailmail S, Tatara E, Swynghedauw B, and Robert V. Cardiac aldosterone production and ventricular remodeling. Kidney Int 57: 1346-1351, 2000.
19. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, and Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 103: 2055-2059, 2001.
20. Doggrell SA and Brown L. The spironolactone renaissance. Expert Opin Investig Drugs 10: 943-954, 2001.
21. Dunn AJ. Cytokine activation of the HPA axis. Ann NY Acad Sci 917: 608-617, 2000.
22. Duprez D, De Buyzere M, Rietzschel ER, and Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep 2: 327-334, 2000.
23. Ericsson A, Arias C, and Sawchenko PE. Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. J Neurosci 17: 7166-7179, 1997.
24. Ericsson A, Kovacs KJ, and Sawchenko PE. A functional anatomical analysis of Central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J Neurosci 14: 897-913, 1994.
25. Eskandari F and Sternberg EM. Neural-immune interactions in health and disease. Ann NY Acad Sci 966: 20-27, 2002.
26. Farman N and Bocchi B. Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int 57: 1364-1369, 2000.
27. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, and McTiernan C. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35: 537-544, 2000.
28. Francis J, Chu Y, Weiss RM, Johnson AK, and Felder RB. Hypothalamus: a novel site for the production of tumor necrosis factor-α after myocardial infarction in rats (Abstract). Circulation 106: 1166, 2002.
29. Francis J, Wei S, Weiss RM, Beltz TG, Johnson AK, and Felder RB. Forebrain-mediated adaptations to myocardial infarction in the rat. Am J Physiol Heart Circ Physiol 282: H1898-H1906, 2002.
30. Francis J, Wei SG, Weiss RM, Johnson AK, and Felder RB. Central but not peripheral infusion of mineralocorticoid receptor antagonist decreases sympathetic drive early after coronary artery ligation in rats (Abstract). FASEB J 16: A791, 2002.
31. Francis J, Weiss RM, and Felder RB. Chronic central infusion of spironolactone decreases plasma tumor necrosis factor in rats with congestive heart failure. Circulation 104: 11-37, 2001.
32. Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K, and Felder RB. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol 281: H2241-H2251, 2001.
33. Francis J, Weiss RM, Wei SG, Johnson AK, and Felder RB. Progression of heart failure after myocardial infarction in the rat. Am J Physiol Regul Integr Comp Physiol 281: R1734-R1745, 2001.
34. Frangogiannis NG, Burns AR, Michael LH, and Entman ML. Histochemical and morphological characteristics of canine cardiac mast cells. Histochem J 31: 221-229, 1999.
35. Frangogiannis NG, Smith CW, and Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31-47, 2002.
36. Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 28: 1002-1006, 2001.
37. Funder JW. Aldosterone and mineralocorticoid receptors: orphan questions. Kidney Int 57: 1358-1363, 2000.
38. Gomez-Sanchez EP. Central hypertensive effects of aldosterone. Front Neuroendocrinol 18: 440-462, 1997.
39. Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T, Nakamura S, Kuwahara K, Saito Y, Nakao K, and Ogawa H. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104: 137-139, 2001.
40. Hori T, Katafuchi T, Take S, Shimizu N, and Niijima A. The autonomic nervous system as a communication channel between the brain and the immune system. Neuroimmunomodulation 2: 203-215, 1995.
41. Jezova D, Ochedalski T, Kiss A, and Aguilera G. Brain angiotensin II modulates sympathoadrenal and hypothalamic pituitary adrenocortical activation during stress. J Neuroendocrinol 10: 67-72, 1998.
42. Johnson AK, de Olmos J, Pastuskovas CV, Zardetto-Smith AM, and Vivas L. The extended amygdala and salt appetite. Ann NY Acad Sci 877: 258-280, 1999.
43. Kovacs KJ and Elenkov IJ. Differential dependence of ACTH secretion induced by various cytokines on the integrity of the paraventricular nucleus. J Neuroendocrinol 7: 15-23, 1995.
44. Lappe RW and Brody MJ. Mechanisms of the central pressor action of angiotensin II in conscious rats. Am J Physiol Regul Integr Comp Physiol 246: R56-R62, 1984.
45. Louis A, Cleland JG, Crabbe S, Ford S, Thackray S, Houghton T, and Clark A. Clinical trials update: CAPRI-CORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 3: 381-387, 2001.
46. McCann SM, Kimura M, Karanth S, Yu WH, Mastronardi CA, and Rettori V. The mechanism of action of cytokines to control the release of hypothalamic and pituitary hormones in infection. Ann NY Acad Sci 917: 4-18, 2000.
47. McKinley MJ, McAllen RM, Pennington GL, Smardencas A, Weisinger RS, and Oldfield BJ. Physiological actions of angiotensin II mediated by AT1 3: S99-S104, 1996.
48. McKinley MJ, Pennington GL, and Oldfield BJ. Anteroventral wall of the third ventricle and dorsal lamina terminalis: headquarters for control of body fluid homeostasis? Clin Exp Pharmacol Physiol 23: 271-281, 1996.
49. Meistrell ME III, Botchkina GI, Wang H, Di Santo E, Cockroft KM, Bloom O, Vishnubhakat JM, Ghezzi P, and Tracey KJ. Tumor necrosis factor is a brain damaging cytokine in cerebral ischemia. Shock 8: 341-348, 1997.
50. Nadeau S and Rivest S. Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier. Neuroscience 93: 1449-1464, 1999.
51. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, and Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98: 794-799, 1998.
52. Oitzl MS and de Kloet ER. Selective corticosteroid antagonists modulate specific aspects of spatial orientation learning. Behav Neurosci 106: 62-71, 1992.
53. Patel KP, Zhang PL, and Krukoff TL. Alterations in brain hexokinase activity associated with heart failure in rats. Am J Physiol Regul Integr Comp Physiol 265: R923-R928, 1993.
54. Peeters AC, Netea MG, Kullberg BJ, Thien T, and van der Meer JW. The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology 94: 376-379, 1998.
55. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 9: 145-149, 1995.
56. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, and Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
57. Ponnappa BC, Dey I, Tu GC, Zhou F, Aini M, Cao QN, and Israel Y. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-α in rats. J Pharmacol Exp Ther 297: 1129-1136, 2001.
58. Rahmouni K, Barthelmebs M, Grima M, Imbs JL, and Wybren De J. Brain mineralocorticoid receptor control of blood pressure and kidney function in normotensive rats. Hypertension 33: 1201-1206, 1999.
59. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats AJ, and Anker SD. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102: 3060-3067, 2000.
60. Rivest S. How circulating cytokines trigger the neural circuits that control the hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology 26: 761-788, 2001.
61. Rivest S, Lacroix S, Vallieres L, Nadeau S, Zhang J, and Laflamme N. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 223: 22-38, 2000.
62. Rocha R and Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 62: 723-731, 2002.
63. Saigusa T. Participation of interleukin-1 and tumor necrosis factor in the responses of the sympathetic nervous system during lipopolysaccharide-induced fever. Pflugers Arch 416: 225-229, 1990.
64. Saindon CS, Blecha F, Musch TI, Morgan DA, Fels RJ, and Kenney MJ. Effect of cervical vagotomy on sympathetic nerve responses to peripheral interleukin-1β. Auton Neurosci 87: 243-248, 2001.
65. Sakai RR, McEwen BS, Fluharty SJ, and Ma LY. The amygdala: site of genomic and nongenomic arousal of aldosterone-induced sodium intake. Kidney Int 57: 1337-1345, 2000.
66. Saravia FE, Grillo CA, Ferrini M, Roig P, Lima AE, de Kloet ER, and De Nicola AF. Changes of hypothalamic and plasma vasopressin in rats with deoxycorticosterone-acetate induced salt appetite. J Steroid Biochem Mol Biol 70: 47-57, 1999.
67. Stadler T, Veltmar A, Qadri F, and Unger T. Angiotensin II evokes noradrenaline release from the paraventricular nucleus in conscious rats. Brain Res 569: 117-122, 1992.
68. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, and Kinoshita M. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor α, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. JAm Coll Cardiol 35: 714-721, 2000.
69. Turnbull AV, Lee S, and Rivier C. Mechanisms of hypothalamic-pituitary-adrenal axis stimulation by immune signals in the adult rat. Ann NY Acad Sci 840: 434-443, 1998.
70. Vahid-Ansari F and Leenen FH. Pattern of neuronal activation in rats with CHF after myocardial infarction. Am J Physiol Heart Circ Physiol 275: H2140-H2146, 1998.
71. Vallee SM, Grillo CA, Gonzalez S, Cosen-Binker L, de Kloet ER, McEwen BS, and De Nicola AF. Further studies in deoxycorticosterone acetate treated rats: brain content of mineralocorticoid and glucocorticoid receptors and effect of steroid antagonists on salt intake. Neuroendocrinology 61: 117-124, 1995.
72. Wilson KM, Sumners C, Hathaway S, and Fregly MJ. Mineralocorticoids modulate central angiotensin II receptors in rats. Brain Res 382: 87-96, 1986.
73. Yau JL, Noble J, and Seckl JR. Continuous blockade of brain mineralocorticoid receptors impairs spatial learning in rats. Neurosci Lett 277: 45-48, 1999.